Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Viewpoint piece makes evidence-based arguments for use of primary prophylaxis as a safer and simpler approach compared to preemptive IgG-guided immunoglobulin replacement therapy in patients getting bispecific antibodies.”
Title: IVIG prophylaxis should be initiated following bispecific antibody therapy in multiple myeloma, regardless of IgG levels
Authors: Rahul Banerjee, Meera Mohan, Kai Rejeski, Benjamin R. Puliafito, Diana D. Cirstea, Gurbakhash Kaur, Shonali Midha, Georgia J McCaughan, Nikhil M Kumar, Nikita Mehra, Bhausaheb Bagal, Noopur S. Raje
You can read the Full Article in Blood Advances.
You can find more posts featuring Robert Orlowski in OncoDaily.
